Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

relacorilant 3pembrolizumab 3cabozantinib 2Mifepristone 2Corlux 2veliparib 1tariquidar 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1Temozolomide 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Cyclophosphamide 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Cortex Neoplasms × tariquidar × Clear all
NCT00071058 2012-09-18

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 10 charts

Adrenal Cortex Neoplasms, Endocrine Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡